Page 2 - Avacta Affimer News Today

Feb 12 2021 Read 707 Times AffyXell Therapeutics, a joint venture between Avacta Group and Daewoong Pharmaceutical (Seoul) has closed a Series A venture capital investment of $7.3 million to develop genetically modified stem cells that will produce and secrete therapeutic proteins in situ in the patient. Established in January 2020, AffyXell has combined Avacta’s Affimer platform with Daewoong’s mesenchymal stem cell (lMSC) platform to produce Affimer molecules generated to suppress immune ...

Published: Feb 04, 2021 By Alex Keown China’s JW Therapeutics, which was co-founded by Juno Therapeutics and Wuxi AppTec, forged a partnership with Thermo Fisher Scientific to ensure non-exclusive  commercial access to Thermo Fisher’s Gibco CTS Dynabeads CD3/CD28. The exclusive agreement will be used to support JW’s clinical development programs for CAR-T (Chimeric Antigen Receptor T-Cells) therapies in China. The deal includes JW Therapeutics’ lead product relmacabta...

Avacta Group plc: Avacta announces AffyXell $7.3 Million Series A Financing Avactas next generation cell and gene therapy joint venture with Daewoong Pharmaceutical secures Series A venture funding Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce that AffyXell Therapeutics ("AffyXell"), the joint venture with Daewoong Pharmaceutical ("Daewoong"), has closed a Series A venture capital investment of $7.3 million to further develop its pip...

Published: Dec 24, 2020 By Alex Keown The European Union (EU) authorized ViiV Healthcare’s Vocabria (cabotegravir injection and tablets) in conjunction with Janssen’s Edurant (rilpivirine tablets) for the treatment of HIV-1 infection in adults who are virologically suppressed. Vocabria is intended for adults who are virologically suppressed on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the ...